## Louise Warnich

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6860741/publications.pdf

Version: 2024-02-01

91 2,190 27 43 papers citations h-index g-index

92 92 92 92 2900

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Title is missing!. Euphytica, 2000, 113, 135-144.	1.2	246
2	Whole-genome sequencing for an enhanced understanding of genetic variation among South Africans. Nature Communications, 2017, 8, 2062.	12.8	88
3	The molecular basis and diagnosis of familial hypercholesterolaemia in South African Afrikaners. Annals of Human Genetics, 1991, 55, 115-121.	0.8	81
4	A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophrenia Research, 2016, 170, 1-17.	2.0	79
5	Identification of three mutations and associated haplotypes in the protoporphyrinogen oxidase gene in South African families with variegate porphyria. Human Molecular Genetics, 1996, 5, 981-984.	2.9	74
6	The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder. Molecular and Cellular Neurosciences, 2018, 88, 300-307.	2.2	70
7	DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 38-49.	4.8	67
8	Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Current Pharmacogenomics and Personalized Medicine, 2011, 9, 191-207.	0.2	62
9	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. OMICS A Journal of Integrative Biology, 2014, 18, 10-14.	2.0	54
10	Elucidation of <i>CYP2D6</i> Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. Annals of Human Genetics, 2010, 74, 340-350.	0.8	53
11	Linkage Disequilibrium Analysis in a Recently Founded Population: Evaluation of the Variegate Porphyria Founder in South African Afrikaners. American Journal of Human Genetics, 1998, 62, 1254-1258.	6.2	46
12	Characterization of the genetic profile of $\langle i \rangle$ CYP2C19 $\langle i \rangle$ in two South African populations. Pharmacogenomics, 2010, 11, 1095-1103.	1.3	46
13	Expression of the SLC11A1 (NRAMP1) 5′-(GT)n repeat: Opposite effect in the presence of â^²237C→T. Blood Cells, Molecules, and Diseases, 2004, 33, 45-50.	1.4	45
14	A microsatellite-based index map of human chromosome 11. Human Molecular Genetics, 1993, 2, 909-913.	2.9	43
15	Analysis of pharmacogenetic traits in two distinct South African populations. Human Genomics, 2011, 5, 265.	2.9	43
16	Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Medical Genetics, 2013, 14, 20.	2.1	42
17	Cytochrome P450 pharmacogenetics in African populations. Drug Metabolism Reviews, 2013, 45, 253-275.	3.6	42
18	Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Human Genetics, 2004, 115, 409-417.	3.8	40

#	Article	IF	CITATIONS
19	H3Africa and the African Life Sciences Ecosystem: Building Sustainable Innovation. OMICS A Journal of Integrative Biology, 2014, 18, 733-739.	2.0	40
20	Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 664-672.	4.8	35
21	Population Genetic Structure of <i>Grapholita molesta</i> (Lepidoptera: Tortricidae) in South Africa. Annals of the Entomological Society of America, 2008, 101, 197-203.	2.5	35
22	Association study in three different populations between the <scp>GPR</scp> 88 gene and major psychoses. Molecular Genetics & Genomic Medicine, 2014, 2, 152-159.	1.2	33
23	Regional localization of α-galactosidase ( <i>GLA</i> ) to Xpter→q22, hexosaminidase B ( <i>HEXB</i> ) to 5q13→qter, and arylsulfatase B ( <i>ARSB</i> ) to5pter→q13. Cytogenetic and Genome Research, 1984, 38, 45-49.	1.1	32
24	Population genetic structure of economically important Tortricidae (Lepidoptera) in South Africa: a comparative analysis. Bulletin of Entomological Research, 2010, 100, 421-431.	1.0	32
25	Next-generation sequencing of pharmacogenes. Pharmacogenetics and Genomics, 2013, 23, 666-674.	1.5	32
26	Detection of a frequent polymorphism in exon 10 of the low-density lipoprotein receptor gene. Human Genetics, 1992, 89, 362.	3.8	29
27	Analysis of the three common mutations in the CARD15 gene (R702W, G908R and 1007fs) in South African colored patients with inflammatory bowel disease. Molecular and Cellular Probes, 2005, 19, 278-281.	2.1	29
28	Characterization of the genetic variation present in CYP3A4 in three South African populations. Frontiers in Genetics, 2013, 4, 17.	2.3	28
29	A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. Journal of Human Genetics, 2009, 54, 261-265.	2.3	27
30	Genetic diversity of woolly apple aphid Eriosoma lanigerum (Hemiptera: Aphididae) populations in the Western Cape, South Africa. Bulletin of Entomological Research, 2005, 95, 187.	1.0	24
31	Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]. Current Pharmacogenomics and Personalized Medicine, 2011, 9, 243-251.	0.2	24
32	The â^'237Câ†'T promoter polymorphism of the SLC11A1 gene is associated with a protective effect in relation to inflammatory bowel disease in the South African population. International Journal of Colorectal Disease, 2006, 21, 402-408.	2.2	23
33	Significance of novel endothelin-B receptor gene polymorphisms in Hirschsprung's disease: predominance of a novel variant (561C/T) in patients with co-existing Down's syndrome. Molecular and Cellular Probes, 2003, 17, 49-54.	2.1	22
34	Molecular diagnosis of hereditary hemochromatosis: application of a newly-developed reverse-hybridization assay in the South African population. Clinical Genetics, 2004, 65, 317-321.	2.0	22
35	Analysis of viral and genetic factors in South African patients with multiple sclerosis. Metabolic Brain Disease, 2006, 21, 156-162.	2.9	22
36	Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 873-884.	3.3	22

#	Article	IF	CITATIONS
37	Morphological and molecular identification of economically important Tortricidae (Lepidoptera) on tropical and subtropical fruit in South Africa. African Entomology, 2007, 15, 269-286.	0.6	21
38	Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics, 2011, 12, 1717-1728.	1.3	21
39	Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities. OMICS A Journal of Integrative Biology, 2016, 20, 557-564.	2.0	21
40	Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in â€~Mode 2' and P5) Tj E	TQ <sub>8</sub> 000	rgBT/Overloc
41	Association of functional polymorphisms of SLC11A1 with risk of esophageal cancer in the South African Colored population. Cancer Genetics and Cytogenetics, 2005, 159, 48-52.	1.0	18
42	Reactions, beliefs and concerns associated with providing hair specimens for medical research among a South African sample: a qualitative approach. Future Virology, 2012, 7, 1135-1142.	1.8	18
43	Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort. Psychiatry Research, 2018, 262, 141-148.	3.3	18
44	Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote. Atherosclerosis, 1996, 125, 111-119.	0.8	17
45	Morphological and molecular identification of economically important Tortricidae (Lepidoptera) on deciduous fruit tree crops in South Africa. African Entomology, 2008, 16, 209-219.	0.6	17
46	Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics, 2014, 15, 189-199.	1.3	17
47	<i>CYP2B6*6</i> and <i>CYP2B6*18</i> Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. AIDS Research and Human Retroviruses, 2016, 32, 529-538.	1.1	16
48	Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 163-169.	4.8	15
49	The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. Pharmacogenetics and Genomics, 2016, 26, 235-242.	1.5	15
50	An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List,― "Health in All Policies,―and "See-Through 21 <sup>st</sup> Century Science and Ethics― OMICS A Journal of Integrative Biology, 2015, 19, 435-442.	2.0	14
51	Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms. Pharmacogenomics, 2017, 18, 105-120.	1.3	14
52	An anonymous human single copy genomic clone, D11S29 (L7) at 11q23, identifies a moderately frequent RFLP. Nucleic Acids Research, 1986, 14, 1920-1920.	14.5	13
53	Highly informative dinucleotide repeat polymorphism at the D11S29 locus on chromosome $11q23$ . Human Genetics, $1992$ , $89$ , $357$ -9.	3.8	13
54	Lack of clinical manifestation of hereditary haemochromatosis in South African patients with multiple sclerosis. Metabolic Brain Disease, 2006, 21, 105-116.	2.9	13

#	Article	IF	CITATIONS
55	Identification of a novel functional deletion variant in the 5'-UTR of the DJ-1 gene. BMC Medical Genetics, 2009, 10, 105.	2.1	12
56	Extended haplotype studies in South African and Dutch variegate porphyria families carrying the recurrent p.R59W mutation confirm a common ancestry. British Journal of Dermatology, 2012, 166, 261-265.	1.5	12
57	Mapping of the variegate porphyria (VP) gene: Contradictory evidence for linkage between VP and microsatellite markers at chromosome 14q32. Human Genetics, 1996, 97, 690-692.	3.8	10
58	Molecular analysis reveals a high mutation frequency in the first untranslated exon of the PPOX gene and largely excludes variegate porphyria in a subset of clinically affected Afrikaner families. Molecular and Cellular Probes, 1998, 12, 293-300.	2.1	10
59	The use of Simple Sequence Repeats (SSRs) to identify commercially important potato (Solanum) Tj ETQq1 1 0.78	34314 rgB <sup>-</sup>	Г <sub>у</sub> Overloc <mark>k</mark>
60	A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?. OMICS A Journal of Integrative Biology, 2014, 18, 663-665.	2.0	9
61	Analysis of population genetic structure of two closely related tortricid species of economic importance on macadamias and litchis in South Africa. Agricultural and Forest Entomology, 2006, 8, 113-119.	1.3	8
62	An anonymous human single copy genomic clone (D8S5) (TL11) on chromosome 8 identifies a moderately frequent RFLP. Nucleic Acids Research, 1986, 14, 6781-6781.	14.5	7
63	Editorial (Forward Look: Tenth Anniversary of the Human Genome Sequence and 21st Century) Tj ETQq1 1 0.7843 and Personalized Medicine, 2011, 9, 148-155.	314 rgBT /0 0.2	Overlock 10 7
64	Editorial (Public Health Pharmacogenomics and the Design Principles for Global Public Goods –) Tj ETQq0 0 0 rg 2013, 11, 1-4.	BT /Overlo 0.2	ock 10 Tf 50 7
65	Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics). OMICS A Journal of Integrative Biology, 2014, 18, 211-221.	2.0	7
66	Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. Pharmacogenomics Journal, 2019, 19, 109-114.	2.0	7
67	Predictors of Abnormal Involuntary Movement in an African Schizophrenia Population. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 317-326.	1.8	6
68	Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace Corps—An Open Letter to World Leaders. OMICS A Journal of Integrative Biology, 2014, 18, 415-420.	2.0	6
69	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications. Big Data, 2013, 1, 196-201.	3.4	5
70	Single nucleotide polymorphisms of the protoporphyrinogen oxidase gene: inter-population heterogeneity of allelic variation. Molecular and Cellular Probes, 2001, 15, 217-221.	2.1	4
71	<i>In silico</i> promoters: modelling of <i>cis</i> â€regulatory context facilitates target predictio. Journal of Cellular and Molecular Medicine, 2009, 13, 270-278.	3.6	4
72	Evaluation of predictive <i>CYP2C19</i> genotyping assays relative to measured phenotype in a South African cohort. Pharmacogenomics, 2015, 16, 1343-1354.	1.3	4

#	Article	lF	CITATIONS
73	Overrepresentation of the founder PPOX gene mutation R59W in a South African patient with severe clinical manifestation of porphyria. Experimental Dermatology, 2005, 14, 50-55.	2.9	3
74	Pharmacogenetics of Antiretroviral Drug Response and Pharmacokinetic Variations in Indigenous South African Populations. OMICS A Journal of Integrative Biology, 2018, 22, 589-597.	2.0	3
75	The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients. Frontiers in Genetics, 2019, 10, 641.	2.3	3
76	Chromosome 22q11 in a Xhosa schizophrenia population. South African Medical Journal, 2012, 102, 165.	0.6	3
77	Iron homeostasis in porphyria cutanea tarda: mutation analysis of promoter regions of <i>CP</i> , <i>CYBRD1</i> , <i>HAMP</i> and <i>SLC40A1</i> . Journal of Clinical Pathology, 2013, 66, 160-161.	2.0	2
78	Special Issue "OMICS IN AFRICA― Power to the People—Moving 21st Century Integrative Biology from Lab to Village to Innovation Ecosystems. OMICS A Journal of Integrative Biology, 2014, 18, 399-401.	2.0	2
79	Gene symbol: DCYTB/CYBRD1. Disease: primary iron overload. Human Genetics, 2005, 118, 548-9.	3.8	2
80	An anonymous DNA probe M7 (D7S422) on chromosome 7 associated with two RFLP's. Nucleic Acids Research, 1990, 18, 5328-5328.	14.5	1
81	Psychiatric genetics in South Africa: cutting a rough diamond. African Journal of Psychiatry, 2011, 14, 355-66.	0.1	1
82	Pharmacogenetics: Relevance to African Healthcare. Current Pharmacogenomics and Personalized Medicine, 2014, 11, 274-287.	0.2	1
83	Haplotype analysis excludes the functional protoporphyrinogen oxidase promoter polymorphism -1081G>A as a modifying factor in the clinical expression of variegate porphyria. Cellular and Molecular Biology, 2002, 48, 57-60.	0.9	1
84	Mapping of the variegate porphyria (VP) gene: contradictory evidence for linkage between VP and microsatellite markers at chromosome 14q32. Human Genetics, 1996, 97, 690-692.	3.8	1
85	An anonymous single copy genomic clone (M8) (D2S13) on chromosome 2 identifies a moderately frequent RFLP. Nucleic Acids Research, 1986, 14, 6780-6780.	14.5	0
86	Three allele RFLP identified by an anonymous sequence on chromosome 2, E135 [D2S62]. Nucleic Acids Research, 1989, 17, 469-469.	14.5	0
87	Anonymous DNA segment H33 [D6S42] on chromosome 6 associated with 2 RFLPs. Nucleic Acids Research, 1989, 17, 468-468.	14.5	0
88	Dinucleotide repeat polymorphism at the D5S99 locus on chromosome 5q33?34. Human Genetics, 1995, 96, 497-9.	3.8	0
89	Genetic research, behavioural science, and child and adolescent mental health in South Africa: an important new agenda. Journal of Child and Adolescent Mental Health, 2008, 20, 73-81.	1.7	0
90	Biotechnology Innovators To Convene in Cape Town, South Africa: Pharmacogenetics and Precision Medicine Conference (April 7–9, 2016). OMICS A Journal of Integrative Biology, 2015, 19, 731-732.	2.0	0

#	Article	IF	CITATIONS
91	Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine – A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia). Current Pharmacogenomics and Personalized Medicine, 2013, 11, 87-92.	0.2	O